BANGKOK, Thailand -- Global efforts to develop a vaccine to prevent HIV infection and AIDS have intensified over the past few years, yet they continue to fall short of what is likely to be needed to achieve success, according to a new report by the International AIDS Vaccine Initiative (IAVI).
Progress is outweighed by significant challenges: the vaccine field is narrowly focused on one concept for how to design a vaccine, is in need of more cooperation and has far too little resources.
IAVI's report, Scientific Blueprint 2004: Accelerating Global Efforts in
AIDS Vaccine Research and Development, was released today at the XV International AIDS Conference in Bangkok, Thailand.
Global efforts toward a vaccine are inadequate despite scientific
consensus that a vaccine is possible, and growing international awareness that a vaccine is essential. According to the United Nations, more people became
infected with HIV last year than in any other year -- 14,000 every day, 5 million total.
"The world is inching toward a vaccine, when we should be making strides," said Dr. Seth Berkley, MD, president and CEO of IAVI. "The single biggest obstacle is that vaccine development is not a top scientific, political and economic priority."
IAVI's Blueprint calls for a doubling of current spending to develop an AIDS vaccine, which at $650 million annually represents less than 1 percent of what the world spends on health product research and development.
More money would help broaden the diversity of vaccine approaches in testing. More than 30 vaccine candidates are in human clinical trials in 19 countries -- a record number. However, these candidates are narrowly focused on one hypothesis for how a vaccine might confer protection.
"Too many scientists are working on the same idea," said Dr. Wayne Koff, IAVI's senior vice president and chief of vaccine research, and the lead author of Scientific Blueprint 2004. "The vaccine field must advance new and
different candidates into trials."
More money would also help expand capacity to conduct vaccine trials in
developing countries, where most new HIV infections occur and different
subtypes of the virus are circulating. A number of developing countries have
sites to conduct small-scale trials, but only Thailand has capacity for large-
scale trials.
IAVI's Blueprint cautions that vaccine candidates are moving forward
without global consensus about how to assess their promise. Vaccine agencies
must agree on common standards so that the best candidates can be quickly
identified and given priority.
At the Bangkok conference, IAVI pledged to expand its own AIDS vaccine
research and development program, which in the past five years has advanced
five vaccine candidates from concept to human trials.
The Bangkok conference's theme is "Access for All." Berkley said: "Access must include treatment and care, prevention and the development of a vaccine."
IAVI is a global not-for-profit organization working to accelerate the development of a vaccine to prevent HIV infection and AIDS. Founded in 1996 and operational in 23 countries, IAVI and its network of collaborators research and develop vaccine candidates.
Source: International AIDS Vaccine Initiative
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.